{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:47:31Z","timestamp":1792291651398,"version":"4.4.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01AI099603\u201305"],"award-info":[{"award-number":["5R01AI099603\u201305"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23 AI132648-05"],"award-info":[{"award-number":["K23 AI132648-05"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most drug-resistant tuberculosis occurs due to transmission of unsuspected or ineffectively treated drug-resistant tuberculosis. The duration of treatment to stop person-to-person spread of drug-resistant tuberculosis is uncertain. We evaluated the impact of novel regimens, including BPaL (bedaquiline, 1200-mg linezolid, and pretomanid), on drug-resistant tuberculosis transmission, using the human\u2013guinea pig (H-GP) transmission model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In experiment 1, patients initiated an optimized drug-resistant tuberculosis regimen including bedaquiline and linezolid. In experiment 2, patients initiated the BPaL regimen. We measured baseline infectivity for each cohort by exhausting ward air to one of two guinea pig exposure rooms (control group), each containing 90 guinea pigs, for 8 patient-days. Then, after 72 hours of treatment, ward air was exhausted to the second guinea pig exposure room for 8 patient-days (intervention group). The infectiousness of each cohort was compared by performing tuberculin skin tests in guinea pigs at baseline (before treatment) and 6 weeks after the exposure period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In experiment 1, before treatment, 5 patients with drug-resistant tuberculosis infected 24 of 90 guinea pigs (26.7%) (control group). After treatment (72 hours after drug initiation), the same patients infected 25 of 90 guinea pigs (27.8%) (intervention group) (P &amp;gt; .99). In experiment 2, before treatment, 9 patients with drug-resistant tuberculosis infected 40 of 90 guinea pigs (44.4%) (control group). After treatment (beginning 72 hours after drug initiation), the same patients infected 0 of 90 guinea pigs (0%) (intervention group) (P &amp;lt; .0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, drug-resistant tuberculosis drug regimens, including bedaquiline and standard-dose linezolid for 72 hours, did not decrease drug-resistant tuberculosis transmission. In contrast, transmission was rapidly and completely inhibited in patients treated with BPaL for 72 hours, suggesting an early and profound impact on transmission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf005","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:19:30Z","timestamp":1736291970000},"page":"143-151","source":"Crossref","is-referenced-by-count":7,"title":["Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis"],"prefix":"10.1093","volume":"232","author":[{"given":"A","family":"Stoltz","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, University of Pretoria School of Medicine , Pretoria ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3544-5021","authenticated-orcid":false,"given":"R R","family":"Nathavitharana","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Beth Israel Deaconess Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3161-1540","authenticated-orcid":false,"given":"E","family":"de Kock","sequence":"additional","affiliation":[{"name":"Retrasol , Pretoria ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4419-3583","authenticated-orcid":false,"given":"V","family":"Ueckermann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Pretoria School of Medicine , Pretoria ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Jensen","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Mendel","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Spigelman","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-3196","authenticated-orcid":false,"given":"E A","family":"Nardell","sequence":"additional","affiliation":[{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"2025073007423339400_jiaf005-B1","volume-title":"Global tuberculosis control. WHO report 2023","author":"World Health Organization","year":"2023"},{"key":"2025073007423339400_jiaf005-B2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1604544","article-title":"Transmission of extensively drug-resistant tuberculosis in South Africa","volume":"376","author":"Shah","year":"2017","journal-title":"N Engl J Med"},{"key":"2025073007423339400_jiaf005-B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(16)30418-2","article-title":"Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation","volume":"17","author":"Yang","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025073007423339400_jiaf005-B4","doi-asserted-by":"crossref","first-page":"e1002149","DOI":"10.1371\/journal.pmed.1002149","article-title":"The tuberculosis cascade of care in India's public sector: a systematic review and meta-analysis","volume":"13","author":"Subbaraman","year":"2016","journal-title":"PLoS Med"},{"key":"2025073007423339400_jiaf005-B5","doi-asserted-by":"crossref","first-page":"S702","DOI":"10.1093\/infdis\/jix335","article-title":"The South African tuberculosis care cascade: estimated losses and methodological challenges","volume":"216","author":"Naidoo","year":"2017","journal-title":"J Infect Dis"},{"key":"2025073007423339400_jiaf005-B6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5588\/ijtld.18.0276","article-title":"Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis","volume":"23","author":"Nathavitharana","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025073007423339400_jiaf005-B7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJMoa022928","article-title":"Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru","volume":"348","author":"Mitnick","year":"2003","journal-title":"N Engl J Med"},{"key":"2025073007423339400_jiaf005-B8","first-page":"511","article-title":"Infectiousness of air from a tuberculosis ward: ultraviolet irradiation of infected air: comparative infectiousness of different patients","volume":"85","author":"Riley","year":"1961","journal-title":"Am Rev Respir Dis"},{"key":"2025073007423339400_jiaf005-B9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.5588\/ijtld.13.0834","article-title":"Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis","volume":"18","author":"Dharmadhikari","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025073007423339400_jiaf005-B10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5588\/ijtld.14.0680","article-title":"F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy","volume":"19","author":"Barrera","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025073007423339400_jiaf005-B11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/infdis\/jiy190","article-title":"Turning off the tap: using the FAST approach to stop the spread of drug-resistant tuberculosis in the Russian Federation","volume":"218","author":"Miller","year":"2018","journal-title":"J Infect Dis"},{"key":"2025073007423339400_jiaf005-B12","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.06125-11","article-title":"Phase II dose-ranging trial of the early bactericidal activity of PA-824","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025073007423339400_jiaf005-B13","volume-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization","year":"2013"},{"key":"2025073007423339400_jiaf005-B14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline\u2014the benefit-risk balance for drug-resistant tuberculosis","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"2025073007423339400_jiaf005-B15","volume-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis","author":"World Health Organization","year":"2014"},{"key":"2025073007423339400_jiaf005-B16","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"2025073007423339400_jiaf005-B17","year":"2017"},{"key":"2025073007423339400_jiaf005-B18","volume-title":"Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children","author":"South African National Department of Health","year":"2018"},{"key":"2025073007423339400_jiaf005-B19","volume-title":"WHO Treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update","author":"World Health Organization","year":"2018"},{"key":"2025073007423339400_jiaf005-B20","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019"},{"key":"2025073007423339400_jiaf005-B21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2025073007423339400_jiaf005-B22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.tube.2011.03.002","article-title":"Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis","volume":"91","author":"Dharmadhikari","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"2025073007423339400_jiaf005-B23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1164\/rccm.201501-0060OC","article-title":"Institutional tuberculosis transmission. Controlled trial of upper room ultraviolet air disinfection: a basis for new dosing guidelines","volume":"192","author":"Mphaphlele","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2025073007423339400_jiaf005-B24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1164\/rccm.201107-1190OC","article-title":"Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward","volume":"185","author":"Dharmadhikari","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2025073007423339400_jiaf005-B25","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"Jindani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2025073007423339400_jiaf005-B26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0041-3879(76)80006-2","article-title":"Transmission of tubercle bacilli: the effects of chemotherapy","volume":"57","author":"Rouillon","year":"1976","journal-title":"Tubercle"},{"key":"2025073007423339400_jiaf005-B27","doi-asserted-by":"crossref","first-page":"e1003566","DOI":"10.1371\/journal.pmed.1003566","article-title":"Dynamics of sputum conversion during effective tuberculosis treatment: a systematic review and meta-analysis","volume":"18","author":"Calderwood","year":"2021","journal-title":"PLoS Med"},{"key":"2025073007423339400_jiaf005-B28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025073007423339400_jiaf005-B29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"2025073007423339400_jiaf005-B30","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/cid\/ciae145","article-title":"Treatment of multidrug-resistant or rifampicin-resistant tuberculosis with an all-oral 9-month regimen containing linezolid or ethionamide in South Africa: a retrospective cohort study","volume":"78","author":"Morgan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025073007423339400_jiaf005-B31","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025073007423339400_jiaf005-B32","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"key":"2025073007423339400_jiaf005-B33","doi-asserted-by":"crossref","first-page":"955050","DOI":"10.3389\/fphar.2022.955050","article-title":"Linezolid resistance in multidrug-resistant Mycobacterium tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Azimi","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025073007423339400_jiaf005-B34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am J Resp Crit Care Med"},{"key":"2025073007423339400_jiaf005-B35","doi-asserted-by":"crossref","first-page":"e02012","DOI":"10.1128\/AAC.02012-19","article-title":"Fourteen-day bactericidal activity, safety, and pharmacokinetics of linezolid in adults with drug-sensitive pulmonary tuberculosis","volume":"64","author":"Diacon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025073007423339400_jiaf005-B36","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","article-title":"Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"2025073007423339400_jiaf005-B37","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2025073007423339400_jiaf005-B38","doi-asserted-by":"crossref","first-page":"17812","DOI":"10.1038\/s41598-021-96902-7","article-title":"Early phase of effective treatment induces distinct transcriptional changes in Mycobacterium tuberculosis expelled by pulmonary tuberculosis patients","volume":"11","author":"Shaikh","year":"2021","journal-title":"Sci Rep"},{"key":"2025073007423339400_jiaf005-B39","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/s41467-021-22833-6","article-title":"Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens","volume":"12","author":"Walter","year":"2021","journal-title":"Nat Commun"},{"key":"2025073007423339400_jiaf005-B40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf005\/61403955\/jiaf005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/1\/143\/61403955\/jiaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/1\/143\/61403955\/jiaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:42:44Z","timestamp":1753875764000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/1\/143\/7950977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,9]]},"published-print":{"date-parts":[[2025,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf005","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2025,1,9]]}}}